By demonstrating its efficacy in ameliorating dysfunction, inflammation, and fibrosis post-AMI via targeted inhibition of the TLR4/MyD88/NF-κB pathway, this study validates its traditional use and offers a compelling candidate for targeted treatment of ischemic heart disease. Here, MYD88 is linked to coronary artery disorder.